ADC Therapeutics SA Form 8-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 8-K dated January 4, 2024, reporting an event that occurred on January 2, 2024. The company is a Switzerland-incorporated biopharmaceutical company whose common shares trade on the New York Stock Exchange under the symbol ADCT.
Material event
The New York Stock Exchange notified the company that it had regained compliance with the NYSE continued listing minimum price requirement under Section 802.01C of the NYSE Listed Company Manual. The company will therefore be removed from the NYSE’s noncompliant issuers list.
The deficiency resulted from the company’s average closing share price being below $1.00 over a consecutive 30-trading-day period. Compliance was restored because both the December 29, 2023 closing price and the average closing price for the 30-trading-day period ending on that date were above $1.00.
Financial metrics and liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Guidance, outlook, risks, and unusual items
The filing does not provide financial guidance, operating outlook, management commentary, contingencies, or new business risks. The reported listing-price deficiency has been cured, but future compliance with NYSE listing standards remains an item investors should monitor.
Key facts to verify
- Confirm the company’s continued compliance with the NYSE minimum share-price requirement.
- Monitor whether the company is formally removed from the NYSE noncompliant issuers list.
- Review subsequent filings for any additional listing notices, reverse-split actions, or other capital-markets developments.
- Obtain the company’s periodic financial filings for current revenue, losses, cash position, debt, liquidity, and operating outlook, which are not included in this 8-K.